Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn how effective the combination of
chemotherapy including both panitumumab, Abraxane (nab-paclitaxel), and carboplatin (PNC) and
fluorouracil, epirubicin, and cyclophosphamide (FEC) used before surgery for the treatment of
IBC is. The safety of PNC combination will also be studied.